Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis

Andrea Roberts(National Cancer Institute), F TIAN(National Cancer Institute), Stacey DaCosta Byfield(National Cancer Institute), Christina H. Stuelten(National Cancer Institute), Akira Ooshima(Wakayama Medical University), Shizuya Saika(Wakayama Medical University), Kathleen C. Flanders(National Cancer Institute)

Cytokine & Growth Factor Reviews

November 12, 2005

10.1016/j.cytogfr.2005.09.008

Cited by 344

Abstract

Related Papers

The microenvironment of the tumour–host interface

Lance A. Liotta, Elise C. Kohn|Nature|2001|2.3k

Putting tumours in context

Mina J. Bissell, Derek C. Radisky|Nature reviews. Cancer|2001|2.2k

Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.

Herbert D. Soule, Terry Maloney, Sandra R. Wolman et al.|PubMed|1990|1.6k

Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response

Gillian S. Ashcroft, Xiao Yang, Adam B. Glick et al.|Nature Cell Biology|1999|912

Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β

Xiao Yang, John J. Letterio, Robert J. Lechleider et al.|The EMBO Journal|1999|902